Gynaecological Cancers
Read Time: 5 mins

Why We Need to Continue to Research Ways to Improve the Treatment of Locally Advanced Cervical Cancer

Copy Link
Published Online: Nov 20th 2015 Oncology & Hematology Review, 2015;11(2):110–12 DOI:
Authors: Linda Mileshkin
Quick Links:
Article Information

Morbidity and mortality from locally advanced cervical cancer continues to be a major problem worldwide. Clinical research has defined the best approaches to standard therapy currently. However, it is essential that international clinical trials in this disease continue to be supported to improve outcomes globally.


Cervical cancer, chemoradiotherapy, HPV


Cervical cancer remains one of the leading causes of cancer-related morbidity and mortality worldwide, and is the fourth leading cause of cancer death in women.1 Human papilloma virus (HPV), particularly types 16 and 18, is significantly associated with subsequent development of cervical cancer, with an increased risk also seen among smokers.2 Cervical cancer incidence has decreased in developed countries since the widespread introduction of cervical screening.3 However, it remains a major health problem in countries without screening programs and in disadvantaged communities within developed countries with screening programs.2,4,5 For example, indigenous Aboriginal and Torres Strait Islander women have double the incidence and five times the mortality risk than other Australians.6–9

Many patients with cervical neoplasia have early lesions detected by Pap smear, which are curable with surgery. However, screening rates are low in women from disadvantaged areas, even in developed countries. Hence we continue to see women present with locally advanced diseases who have much lower cure rates.10–12 In addition, there difficulties continue with detecting the precursors of adenocarcinomas using Pap smears.

The development of the cervical cancer vaccine is a major advance, which will reduce cervical cancer rates for future generations. Realizing the benefit of the vaccine is predicted to take some time given that the incidence of cervical cancer continues to rise with age, and that ongoing screening will be required in addition to the vaccine program, which needs to be initiated prior to the age of commencement of sexual activity to be effective. The current vaccine that has been in clinical use is predicted to protect against 70 % of cervical cancer, but does not provide protection for the 30 % of chronic infections by HPV types other than HPV 6, 11, 16, and 18 and has no role in the treatment of established cancer.1 However, in December 2014, the US Food and Drug Administration (FDA) approved a nonavalent vaccine, which offers protection against seven high-risk HPV subtypes and appears even more effective. A UK modeling analysis suggests that 60 years of an ongoing vaccination program of 12-yearold girls at 80 % coverage will be required to see a 38–82 % reduction in cervical cancer incidence if vaccine protection lasts for 20 years on average.13 Unfortunately, many countries worldwide still have neither screening nor vaccination programs so the need to treat locally advanced cervical cancer will remain a problem in our community for many years and needs ongoing research.

The use of low-dose chemotherapy concurrent with pelvic radiation has been proven to improve survival for locally advanced cervical cancer.14 The Medical Research Council (MRC) individual patient data meta-analysis found that the addition of concurrent chemotherapy to radiation increased the 5-year overall survival rate by 6 % (HR 0.81: 60 versus 66 %).15 On the basis of the studies in this analysis, weekly cisplatin at a dose of 40 mg/m2 during pelvic radiation has become the standard of care for the treatment of locally advanced disease. However, the 5-year disease-free survival rate was only 58 % in the chemoradiation group, which, although superior to 50 % with radiation alone, still leaves significant room for improvement. Although chemoradiation is a generally effective treatment for the primary disease, those who relapse tend to develop distant metastatic disease, and often die from their disease in under a year.16

Recognized pretreatment disease factors that predict worse outcomes with standard chemoradiation include a larger tumor volume, particularly if >50 cc; a higher International Federation of Gynecology and Obstetrics (FIGO) stage; uterine corpus invasion; nodal involvement; and continued smoking.17–19 Although nodal involvement is not part of the current clinical FIGO staging system, this can be noninvasively determined using positron emission tomography–computed tomography (PET/CT), with a reported sensitivity of approximately 75 % and specificity of 92 %.20,21

Although the development of distant disease after chemoradiation is the predominant cause of treatment failure, local relapse remains a problem that causes significant morbidity. In the meta-analysis, locoregional treatment failure was responsible for 35 % of the failure events across trials. Standard radiation treatment usually involves 45–50.4 Gy of external beam radiation therapy (EBRT) delivered in fractions of 1.8–2 Gy to the pelvis ± a parametrial or nodal boost. In addition to EBRT, brachytherapy direct to the primary is considered to be essential to give a sufficient curative dose to the primary. There is a recent concern about declining use of brachytherapy as part of chemoradiation in some countries, such as the US. Instead there has been interest in using more modern forms of radiotherapy, such as intensity modulated radiation therapy or stereotactic radiotherapy, which may be less labor intensive, be associated with higher clinician reimbursement, and not require specific brachytherapy training. However, recent reports from large prospective databases suggest that survival rates are clearly inferior in those women who do not receive brachytherapy.22–24 Ongoing approaches to try and optimize brachytherapy include the use of conformal brachytherapy to prescribe the dose to the residual tumor at the end of EBRT rather than the historical point A as well as the use of image guidance using either magnetic resonance imaging (MRI) or ultrasound to ensure the tandem is accurately placed within the uterus to minimize toxicity and maximize efficacy.25,26

A variety of approaches to intensifying the concurrent chemotherapy component of chemoradiation have been tested, such as adding additional systemic therapy. However, to date no additional regimen has been found to be significantly superior to cisplatin 40 mg/m2 weekly. The meta-analysis does suggest efficacy from nonplatinum regimens, and substituting other agents such as carboplatin or fluorouracil may be considered for women with contraindications to cisplatin.27,28 A variety of clinical trials have concluded that adding additional agents to cisplatin (such as gemcitabine, paclitaxel, tirapazamine, and cetuximab) have increased toxicity rates without clearly improving outcomes.29,30 More promising results have been seen with recent small single-arm trials, which have added bevacizumab or triapine to cisplatin, and these approaches may be further evaluated in further randomized trials.31,32

Given the main cause of treatment failure is distant metastasis, it may be that adding further chemotherapy to chemoradiation will help. A subset analysis of the MRC meta-analysis involving two trials, which gave additional adjuvant chemotherapy after chemoradiation showed an impressive absolute improvement of 19 % in 5-year survival (from 60 % to 79 %) compared with radiation alone.33,34 More recently, Duenas- Gonzalez et al. showed a benefit of adding concurrent gemcitabine to standard cisplatin-based chemoradiation, followed by two further cycles of adjuvant cisplatin-gemcitabine. This multicenter randomized phase III trial performed in South America showed a statistically significant 9 % improvement in the primary outcome of progression-free survival at 3 years (65–74 %).35 Limitations of the study include concern about toxicity rates (grade 3–4 toxicities 86.5 versus 46.3 %), as well as the fact that follow-up data were truncated at 1 year.16,36 It remains unclear how much the additional chemotherapy given concurrent with radiation improved outcomes, as opposed to increasing toxicity, with a recent randomized trial addressing this question closed early for futility.37 It is possible that the two cycles of adjuvant chemotherapy were the part of the treatment of most benefit. There is sufficient evidence to suggest a potential role for adjuvant chemotherapy to result in this being further assessed in the ongoing randomized OUTBACK trial of the Gynecologic Cancer InterGroup (GCIG), which is testing whether or not giving four additional cycles of carboplatin and paclitaxel after standard chemoradiation can improve overall survival rates (NCT01414608). Other approaches being tested in ongoing international randomized trials include the value of adding additional neoadjuvant chemotherapy prior to chemoradation (NCT01566240), and comparison of three weekly with weekly cisplatin chemotherapy during radiation (NCT01561586). There is also interest in testing shorter radiation fraction schedules that may be easier and more practical to deliver in areas of the developing world where access to radiotherapy machines remains problematic. As the majority of the burden of cervical cancer is seen in the developing world, it is essential that ongoing efforts continue to improve access not only to preventive measures such as screening and vaccination but also to treatments and clinical trials for those who present with established disease.

Article Information:

Linda Mileshkin, MD, has nothing to declare in relation to this article. No funding was received in the publication of this article.


Linda Mileshkin, MD, Medical Oncologist, Division of Cancer Medicine, Peter MacCallum Cancer Centre, Locked Bag 1, A’Beckett St, Vic 8006, Australia. E:


This article is published under the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, adaptation, and
reproduction provided the original author(s) and source are given appropriate credit.




1. Jemal A, Bray F, Center MM, et al., Global cancer statistics, CA Cancer J Clin, 2011;61:69–90.
2. Barbera L, Thomas G, Management of early and locally advanced cervical cancer, Semin Oncol, 2009;36:155–69.
3. Kamangar F, Dores GM, Anderson WF, Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world, J Clin Oncol, 2006;24:2137–50.
4. Downs LS, Smith JS, Scarinci I, et al., The disparity of cervical cancer in diverse populations, Gynecol Oncol, 2008;109 (Suppl. 2):S22–30.
5. Quinn MA, Benedet JL, Odicino F, et al., Carcinoma of the cervix uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer, Int J Gynaecol Obstet, 2006;95(Suppl. 1):S43–103.
6. Cervical Screening in Australia 2006–2007, Canberra: Australian Institute of Health and Welfare, 2009. Available at: https://www. (accessed October 23, 2015).
7. O’Brien ED, Bailie RS, Jelfs PL, Cervical cancer mortality in Australia: contrasting risk by aboriginality, age and rurality, Int J Epidemiol, 2000;29:813–6.
8. Luke C, Nguyen AM, Heard A, et al., Benchmarking epidemiological characteristics of cervical cancer in advance of change in screening practice and commencement of vaccination, Aust N Z J Public Health, 2007;31:149–54.
9. Shannon GD, Franco OH, Powles J, et al., Cervical cancer in Indigenous women: the case of Australia, Maturitas, 2011;70:234–45.
10. Spayne J, Ackerman I, Milosevic M, et al., Invasive cervical cancer: a failure of screening, Eur J Public Health, 2008;18:162–5.
11. Yang B, Morrell S, Zuo Y, et al., A case-control study of the protective benefit of cervical screening against invasive cervical cancer in NSW women, Cancer Causes Control, 2008;19:569–76.
12. Coory MD, Fagan PS, Muller JM, Dunn NA, Participation in cervical cancer screening by women in rural and remote Aboriginal and Torres Strait Islander communities in Queensland, Med J Aust, 2002;177:544–7.
13. Choi YH, Jit M, Gay N, Cox A, et al., Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom, Vaccine 2010;28:4091–102.
14. NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer, National Comprehensive Cancer Network, Inc 2011; Version 1.2012.
15. Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration, Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials, J Clin Oncol, 2008;26:5802–12.
16. Friedlander M, Grogan M, Guidelines for the treatment of recurrent and metastatic cervical cancer, Oncologist, 2002;7:342–7.
17. Narayan K, Fisher RJ, Bernshaw D, et al., Patterns of failure and prognostic factor analyses in locally advanced cervical cancer patients staged by positron emission tomography and treated with curative intent, Int J Gynecol Cancer, 2009;19:912–8.
18. Monk BJ, Tian C, Rose PG, Lanciano R, Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials, Gynecol Oncol, 2007;105:427–33.
19. Mileshkin L, Paramanathan A, Kondalsamy-Chennakesavan S,et al., Smokers with cervix cancer have more uterine corpus invasive disease and an increased risk of recurrence after treatment with chemoradiation, Int J Gynecol Cancer, 2014; 24:1286–91.
20. Wright JD, Dehdashti F, Herzog TJ, et al., Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro- 2-deoxy-D-glucose-positron emssion tomography, Cancer, 2005;104:2484–91.
21. Rose PG, Adler LP, Rodriguez M, et al., Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study, J Clin Oncol, 1999;17:41–5.
22. Gill BS, Lin JF, Krivak TC, et al., National Cancer Data Base analysis of radiation therapy consolidation modality for cervical cancer: the impact of new technological advancements, Int J Radiat Oncol Biol Phys, 2014;90:1083–90.
23. Petereit DG, Frank SJ, Viswanathan AN, et al., Brachytherapy: where has it gone?, J Clin Oncol, 2015;33:980–2.
24. Han K, Milosevic M, Fyles A, et al., Trends in the utilization of brachytherapy in cervical cancer in the United States, Int J Radiat Oncol Biol Phys, 2013;87:111–9.
25. Narayan K, Van Dyk S, Bernshaw D, et al., Ultrasound guided conformal brachytherapy of cervix cancer: survival, patterns of failure, and late complications, J Gynecol Oncol, 2014;25:206–13.
26. Van Dyk S, Kondalsamy-Chennakesavan S, Schneider M, et al., Comparison of measurements of the uterus and cervix obtained by magnetic resonance and transabdominal ultrasound imaging to identify the brachytherapy target in patients with cervix cancer, Int J Radiat Oncol Biol Phys, 2014;88:860–5.
27. Au-Yeung G, Mileshkin L, Bernshaw D, et al., Radiation with cisplatin or carboplatin for locally advanced cervix cancer: the experience of a tertiary cancer centre, J Med Imaging Radiat Oncol, 2013;57:97–104.
28. Lanciano R, Calkins A, Bundy BN, et al., Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study, J Clin Oncol, 2005;23:8289–95.
29. Moore KN, Sill MW, Miller DS, A phase 1 trials of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: a gynecologic oncology group study, Gynecol Oncol, 2012;127:456–61.
30. DiSilvestro PA, Ali S, Craighead PS, et al., Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study, J Clin Oncol, 2014;32:458–64.
31. Schefter T, Winter K, Kwon JS, RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma, Int J Radiat Oncol Biol Phys, 2014;88:101–5.
32. Kunos CA, Sherertz TM, Long-term disease control with triapine based radiochemotherapy for patients with stage IB2-IIIB cervical cancer, Front Oncol, 2014;4:184.
33. Kantardzic N, Beslija S, Begic D, Comparative parameters of myelotoxicity in patients treated with simultaneous chemotherapy and radiotherapy or only radiotherapy, Med Arh, 2004;58:19–22.
34. Peters WA, 3rd, Liu PY, Barrett RJ, 2nd, et al., Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix, J Clin Oncol, 2000;18:1606–13.
35. Duenas-Gonzalez A, Zarba JJ, Patel F, et al., Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix, J Clin Oncol, 2011;29:1678–85.
36. Thomas G, Are we making progress in curing advanced cervical cancer?, J Clin Oncol, 2011;29:1654–6.
37. Wang CC, Chou HH, Yang LY, et al., A randomized trial comparing concurrent chemoradiotherapy with single-agent cisplatin versus cisplatin plus gemcitabine in patients with advanced cervical cancer: an Asian Gynecologic Oncology Group study, Gynecol Oncol, 2015;137:462–7.

Further Resources

Share this Article
Related Content In Gynaecological Cancers
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72